Valuation Edwards Lifesciences Corporation
Stocks
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.66 USD | +1.77% |
|
+5.45% | +9.87% |
| 08-06 | Carvolix Secures Up to €30m in Financing |  |
| 07-29 | Edwards Lifesciences Insider Sold Shares Worth $818,958, According to a Recent SEC Filing | MT |
Company Valuation: Edwards Lifesciences Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,883 | 46,128 | 46,246 | 43,663 | 49,471 | 53,046 | - | - |
| Change | - | -42.97% | 0.25% | -5.58% | 13.3% | 7.23% | - | - |
| Enterprise Value (EV) 1 | 80,616 | 45,956 | 45,198 | 40,285 | 45,843 | 49,415 | 47,851 | 46,036 |
| Change | - | -42.99% | -1.65% | -10.87% | 13.8% | 7.79% | -3.16% | -3.79% |
| P/E | 54.4x | 30.6x | 33.2x | 10.6x | 46.6x | 36.4x | 27.9x | 24.8x |
| PBR | 13.9x | 7.82x | 6.99x | 4.36x | 4.79x | 5x | 4.35x | 4.03x |
| PEG | - | 12.14x | -5.79x | 0x | -0.6x | 1x | 0.9x | 2x |
| Capitalization / Revenue | 15.5x | 8.57x | 7.7x | 8.03x | 8.15x | 7.85x | 7.14x | 6.49x |
| EV / Revenue | 15.4x | 8.54x | 7.53x | 7.41x | 7.56x | 7.31x | 6.44x | 5.63x |
| EV / EBITDA | 46.6x | 23.7x | 24.1x | 24.1x | 25.5x | 23.1x | 20.1x | 17.1x |
| EV / EBIT | 50.6x | 25.6x | 26.1x | 26.6x | 27.9x | 25.1x | 21.6x | 18.5x |
| EV / FCF | 57.3x | 47.2x | 47.9x | 139x | 34.3x | 58.2x | 29.7x | 25.3x |
| FCF Yield | 1.74% | 2.12% | 2.09% | 0.72% | 2.91% | 1.72% | 3.36% | 3.95% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 2.38 | 2.44 | 2.3 | 6.97 | 1.83 | 2.531 | 3.304 | 3.718 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5,232 | 5,382 | 6,005 | 5,440 | 6,068 | 6,759 | 7,429 | 8,177 |
| EBITDA 1 | 1,729 | 1,936 | 1,879 | 1,670 | 1,800 | 2,137 | 2,384 | 2,687 |
| EBIT 1 | 1,594 | 1,796 | 1,734 | 1,514 | 1,644 | 1,971 | 2,212 | 2,484 |
| Net income 1 | 1,503 | 1,522 | 1,402 | 4,175 | 1,074 | 1,435 | 1,897 | 2,121 |
| Net Debt 1 | -267 | -172.7 | -1,048 | -3,378 | -3,628 | -3,631 | -5,195 | -7,011 |
| Reference price 2 | 129.55 | 74.61 | 76.25 | 74.03 | 85.25 | 92.03 | 92.03 | 92.03 |
| Nbr of stocks (in thousands) | 624,334 | 618,260 | 606,500 | 589,800 | 580,300 | 576,400 | - | - |
| Announcement Date | 1/26/22 | 1/31/23 | 2/6/24 | 2/11/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 36.36x | 7.33x | 23.19x | -.--% | 53.05B | |
| 29.86x | 5.3x | 20.3x | 0.31% | 222B | |
| 35.09x | 6.35x | 20.12x | 0.69% | 147B | |
| 43.16x | 11.25x | 24.86x | -.--% | 139B | |
| 18.87x | 3.83x | 12.44x | -.--% | 73.13B | |
| 19.62x | 2.33x | 11.73x | 2.6% | 50.36B | |
| 28.92x | 5.74x | 19.62x | 0.69% | 42B | |
| 83.62x | 6.85x | 20.76x | -.--% | 40.43B | |
| 15.62x | 1.79x | 10.03x | 0.22% | 32.95B | |
| 20.78x | 5.46x | 13.95x | 1.1% | 31.74B | |
| Average | 33.19x | 5.62x | 17.70x | 0.56% | 83.15B | |
| Weighted average by Cap. | 33.49x | 6.26x | 19.34x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EW Stock
- Valuation Edwards Lifesciences Corporation
Select your edition
All financial news and data tailored to specific country editions
